Keywords: Pfizer, Tofacitinib, Ulcerative colitis, Ph II

Pfizer RA drug candidate tofacitinib shows promise in ulcerative colitis

Article | 16 August 2012

Print This

Patients with moderately to severely active ulcerative colitis treated with drug behemoth Pfizer’s (NYSE PFE) tofacitinib were more ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in